Dr Hiroshi Takumida, MD, PhD is an expert in Oncology at University of Tokyo (Japan). Hiroshi Takumida has authored 17 publications, the most recent in 2025. SLR score: 45 (community average: 125). How the SLR is computed.

LeadR Profile

Dr Hiroshi Takumida, MD, PhD University of Tokyo Japan
45 ScienceLeadR Reputation 45
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2025

Source: PubMed

University of Tokyo

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 17

Citations

Citations: 124 1st author: 7 Last author: 0 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer.
PMID 40842416 — cells, lung, micrornas, neoplasms, pathology, lung neoplasms, small cell lung carcinoma, enhancer elements, genetic, tumor microenvironment
J Pathol20250
Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer.
PMID 40595415 — oncogenes, cells, genes, gene expression profiling, lung, transcriptome, neoplasms, lung neoplasms, small cell lung carcinoma, epigenome
Oncogene20250
Diagnostic accuracy of direct reverse transcription-polymerase chain reaction using guanidine-based and guanidine-free inactivators for SARS-CoV-2 detection in saliva samples.
PMID 38452822 — infections, rna, virology, sars virus, reverse transcriptase polymerase chain reaction, guanidine, reverse transcription, covid-19, sars-cov-2
J Virol Methods20240
High-flow nasal cannula for severe COVID-19 patients in a Japanese single-center, retrospective, observational study: 1 year of clinical experience.
PMID 36865899 — infections, positive-pressure respiration, therapeutics, history, cannula, covid-19, sars-cov-2
Glob Health Med20230
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
PMID 34389874 — safety, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, therapeutics, chemotherapy
Cancer Immunol Immunother20218

LeadR Networks

Main global connection map